Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00003308 · ClinicalTrials.gov registry record · Phase 2

Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma

A Phase 2 study of Ovarian Cancer and Sarcoma, sponsored by Eastern Cooperative Oncology Group.

Completed
Registry status
Phase 2
Development phase
14
Study locations

NCT00003308 is a Phase 2 study of Ovarian Cancer and Sarcoma that has completed, run by Eastern Cooperative Oncology Group. The trial reports 14 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00003308, a Phase 2 study of Ovarian Cancer and Sarcoma, has completed, sponsored by Eastern Cooperative Oncology Group.

COMPLETED
Registry status
Phase 2
Development phase
14
Study locations

Study Summary

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. PURPOSE: Phase II trial to study the effectiveness of radiation therapy in treating patients with newly diagnosed brain metastases from kidney cancer, melanoma, or sarcoma.

Interventions

  • RADIATION stereotactic radiosurgery

Study Locations (14)

Iowa

  • Iowa Methodist Medical Center - Des Moines
  • Mercy Medical Center - Des Moines
  • Iowa Lutheran Hospital - Des Moines

Wisconsin

  • CCOP - St. Vincent Hospital Cancer Center, Green Bay - Green Bay
  • Veterans Affairs Medical Center - Madison - Madison
  • University of Wisconsin Comprehensive Cancer Center - Madison

Other

  • Instituto de Enfermedades Neoplasicas - Lima
  • San Juan City Hospital - San Juan

Michigan

  • CCOP - Kalamazoo - Kalamazoo

Nebraska

  • Alegent Health-Midlands Community Hospital - Papillion

New Mexico

  • MBCCOP - University of New Mexico HSC - Albuquerque

Ohio

  • Ireland Cancer Center - Cleveland

Pennsylvania

  • Milton S. Hershey Medical Center - Hershey

Trial Details

FieldValue
Start Date 1999-02-02
Phase Phase 2

Sponsor

Eastern Cooperative Oncology Group

141 total trials

What the Registry Record Tells You About NCT00003308

The ClinicalTrials.gov registry entry for NCT00003308 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which stereotactic radiosurgery is the first listed.

NCT00003308 reports 14 study locations spanning 9 distinct geographic areas - top geographies include Iowa, Wisconsin, Other.

Frequently Asked Questions

What is clinical trial NCT00003308 about?

NCT00003308 is a clinical study titled "Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma". RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. PURPOSE: Phase II trial to study the effectiveness of radiation therapy in treating patients with newly diagnosed brain metastases from kidney cancer, melanoma, or sarcoma.

What is the current status of trial NCT00003308?

This trial is currently completed. It is a Phase 2 study. The study started on 1999-02-02.

What conditions does trial NCT00003308 study?

This clinical trial studies the following conditions: Ovarian Cancer, Sarcoma, Metastatic Cancer, Kidney Cancer, Melanoma (Skin).

What interventions are being tested in trial NCT00003308?

The interventions under investigation include: stereotactic radiosurgery (RADIATION).

Who is sponsoring clinical trial NCT00003308?

This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00003308 being conducted?

This trial has 14 study locations across Iowa, Michigan, Nebraska, New Mexico, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.